Apricus Biosciences Announces 2010 Third Quarter Financial Results Conference Call
Apricus Biosciences, Inc. (“Apricus Bio”) (Nasdaq: APRI), announced today that management will hold a conference call to discuss 2010 third quarter financial results and ongoing corporate activities, on Friday, November 12, 2010 at 12:00 p.m. ET. The Company will file its Form 10-Q by the open of business on Friday, November 12, 2010.
The call can be accessed in the U.S. by dialing (877) 407-8031 and outside of the U.S. by dialing (201) 689-8031 and asking the conference operator for the Apricus Bio Conference Call. The teleconference replay will be available for one week by dialing in the U.S. (877) 660-6853 and outside of the U.S. by dialing (201) 612-7415. Replay pass codes 286 and 360911 are both required for playback. The conference call will also be Webcast live at http://www.investorcalendar.com/IC/CEPage.asp?ID=162504. The Webcast replay will be available for three months.
About Apricus Biosciences
Backed by NexMed, USA and Bio-Quant, Inc., its revenue generating CRO
business, Apricus Bio has leveraged the flexibility of its proven NexACT
drug delivery technology to enable multi-route administration of new and
improved compounds across numerous therapeutic classes. Future growth is
expected to be driven primarily through out-licensing of this technology
for the development and commercialization of such compounds to
pharmaceutical and biotechnology companies, worldwide. Concurrently, the
Company is seeking to monetize its existing product pipeline, including
compounds from pre-clinical through Phase 3, currently focused on
dermatology, sexual dysfunction and cancer. For further information on
Apricus Bio and its subsidiaries, visit
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV